Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Sales (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Return on Sales data on record, last reported at 0.13% in Q3 2025.

  • For Q3 2025, Return on Sales fell 5.0% year-over-year to 0.13%; the TTM value through Sep 2025 reached 0.09%, up 30.0%, while the annual FY2024 figure was 0.05%, 2.0% down from the prior year.
  • Return on Sales reached 0.13% in Q3 2025 per PLX's latest filing, up from 0.01% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.94% in Q4 2021 and bottomed at 1.77% in Q2 2021.
  • Average Return on Sales over 5 years is 0.25%, with a median of 0.25% recorded in 2022.
  • Peak YoY movement for Return on Sales: tumbled -139bps in 2021, then soared 116bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.94% in 2021, then crashed by -140bps to 0.37% in 2022, then plummeted by -54bps to 0.57% in 2023, then skyrocketed by 162bps to 0.36% in 2024, then plummeted by -63bps to 0.13% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.13% in Q3 2025, 0.01% in Q2 2025, and 0.36% in Q1 2025.